3.8 Review

Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer

Journal

IMMUNOTARGETS AND THERAPY
Volume 7, Issue -, Pages 1-14

Publisher

DOVE MEDICAL PRESS LTD
DOI: 10.2147/ITT.S134834

Keywords

immunosuppression; tumor microenvironment; immunotherapy; imaging; phosphatidylserine; bavituximab

Categories

Funding

  1. Peregrine Pharmaceuticals, Inc., Tustin, CA, USA

Ask authors/readers for more resources

Phosphatidylserine (PS) is a negatively charged phospholipid in all eukaryotic cells that is actively sequestered to the inner leaflet of the cell membrane. Exposure of PS on apoptotic cells is a normal physiological process that triggers their rapid removal by phagocytic engulfment under noninflammatory conditions via receptors primarily expressed on immune cells. PS is aberrantly exposed in the tumor microenvironment and contributes to the overall immunosuppressive signals that antagonize the development of local and systemic antitumor immune responses. PS-mediated immunosuppression in the tumor microenvironment is further exacerbated by chemotherapy and radiation treatments that result in increased levels of PS on dying cells and necrotic tissue. Antibodies targeting PS localize to tumors and block PS-mediated immunosuppression. Targeting exposed PS in the tumor microenvironment may be a novel approach to enhance immune responses to cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available